Your new experience awaits. Try the new design now and help us make it even better

RETRACTION article

Front. Oncol., 10 February 2026

Sec. Women's Cancer

Volume 16 - 2026 | https://doi.org/10.3389/fonc.2026.1798367

Retraction: A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer

This article is a retraction of:

  1. RETRACTED: A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer

    1. Read original article
Frontiers Editorial Office* Frontiers Editorial Office*

    A Retraction of the Clinical Trial Article
    A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer

    By Hu N, Zhu A, Si Y, Yue J, Wang X, Wang J, Ma F, Xu B and Yuan P (2021) Front. Oncol. 10:565384. doi: 10.3389/fonc.2020.565384

    Following publication, significant concerns were raised regarding the integrity of the patient data and reporting within the manuscript. An investigation was conducted in accordance with Frontiers’ policies, and it was determined that the conclusions and assertions were not sufficiently supported by the findings from the material provided; therefore, the article has been retracted.

    This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.

    Citation: Frontiers Editorial Office (2026) Retraction: A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer. Front. Oncol. 16:1798367. doi: 10.3389/fonc.2026.1798367

    Received: 28 January 2026; Accepted: 28 January 2026;
    Published: 10 February 2026.

    Approved by:

    Sharon R. Pine, University of Colorado Anschutz Medical Campus, United States

    Copyright © 2026 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    *Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.